Abstract
A common side effect of cancer treatment is bone marrow suppression. The resulting myelosuppression and anemia can cause significant morbidity and mortality for patients. Agents such as granulocyte colony stimulating factors (GCSF) and erythropoietin stimulating agents (ESAs) may be helpful to ameliorate this depression of blood counts; however these agents have risks which also need to be carefully weighed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 237-241 |
| Number of pages | 5 |
| Journal | Molecular Oncology |
| Volume | 6 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 2012 |
| Externally published | Yes |
Fingerprint
Keywords
- Erythropoietin stimulating agents (ESAs)
- Granulocyte colony stimulating factors (GCSF)
- Pegfilgastrim
ASJC Scopus subject areas
- Cancer Research
- Genetics
- Molecular Medicine
Cite this
Hematopoietic growth factors : Personalization of risks and benefits. / Puhalla, Shannon; Bhattacharya, Saveri; Davidson, Nancy E.
In: Molecular Oncology, Vol. 6, No. 2, 04.2012, p. 237-241.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hematopoietic growth factors
T2 - Personalization of risks and benefits
AU - Puhalla, Shannon
AU - Bhattacharya, Saveri
AU - Davidson, Nancy E.
PY - 2012/4
Y1 - 2012/4
N2 - A common side effect of cancer treatment is bone marrow suppression. The resulting myelosuppression and anemia can cause significant morbidity and mortality for patients. Agents such as granulocyte colony stimulating factors (GCSF) and erythropoietin stimulating agents (ESAs) may be helpful to ameliorate this depression of blood counts; however these agents have risks which also need to be carefully weighed.
AB - A common side effect of cancer treatment is bone marrow suppression. The resulting myelosuppression and anemia can cause significant morbidity and mortality for patients. Agents such as granulocyte colony stimulating factors (GCSF) and erythropoietin stimulating agents (ESAs) may be helpful to ameliorate this depression of blood counts; however these agents have risks which also need to be carefully weighed.
KW - Erythropoietin stimulating agents (ESAs)
KW - Granulocyte colony stimulating factors (GCSF)
KW - Pegfilgastrim
UR - http://www.scopus.com/inward/record.url?scp=84860445233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860445233&partnerID=8YFLogxK
U2 - 10.1016/j.molonc.2012.03.001
DO - 10.1016/j.molonc.2012.03.001
M3 - Article
C2 - 22497867
AN - SCOPUS:84860445233
VL - 6
SP - 237
EP - 241
JO - Molecular Oncology
JF - Molecular Oncology
SN - 1574-7891
IS - 2
ER -